Petros Pharmaceuticals, Inc.
PTPI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $6 | $6 | $8 |
| % Growth | -12.2% | -2.8% | -23.3% | – |
| Cost of Goods Sold | $1 | $2 | $2 | $2 |
| Gross Profit | $4 | $4 | $4 | $6 |
| % Margin | 76.3% | 72% | 61.8% | 79.5% |
| R&D Expenses | $3 | $2 | $2 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $9 | $9 | $12 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $10 | $6 | $10 | $7 |
| Operating Expenses | $22 | $18 | $24 | $24 |
| Operating Income | -$18 | -$14 | -$20 | -$18 |
| % Margin | -345.8% | -233.9% | -332.4% | -231.1% |
| Other Income/Exp. Net | $3 | $5 | -$0 | $9 |
| Pre-Tax Income | -$14 | -$8 | -$20 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$8 | -$20 | -$9 |
| % Margin | -280.1% | -140.2% | -334.4% | -115% |
| EPS | -3.34 | -6.35 | -9.68 | -8.25 |
| % Growth | 47.4% | 34.4% | -17.3% | – |
| EPS Diluted | -3.34 | -6.35 | -9.68 | -8.25 |
| Weighted Avg Shares Out | 8 | 1 | 2 | 1 |
| Weighted Avg Shares Out Dil | 8 | 2 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $0 |
| Depreciation & Amortization | $3 | $3 | $6 | $7 |
| EBITDA | -$11 | -$4 | -$14 | -$2 |
| % Margin | -211.5% | -72.3% | -229.1% | -22.3% |